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Available online 14 July 2016Objective. Nearly 50% of patients who are diagnosed with locally advanced cervical cancer have an unfavor-
able pathological response to conventional treatment. MicroRNAs (miRNAs) are potential biomarkers in cervical
cancer; however, their role in identifying patientswho do not respond to conventional treatment remains poorly
investigated. Here, we identify a set of miRNAs that can be used asmolecular markers to predict the pathological
response in locally advanced cervical cancer patients receiving radiation and chemotherapy treatment.
Methods. Forty-one patients diagnosed with locally advanced cervical cancer were invited to participate in
this study and enrolled after they signed an informed consent. Two patient cohorts were randomized for
miRNA expression proﬁling, a discovery cohort (n = 10) and a validation cohort (n = 31); proﬁling was per-
formed bymeans of a miScript miRNA PCR Array. After amedian clinical follow-up of 45months, statistical anal-
ysis was performed to identify miRNAs that could discriminate non-responders from complete pathological
responders to conventional treatment.
Results.miRNA expression proﬁling identiﬁed 101miRNAs that showed signiﬁcant differences between non-
responders and complete pathological responders (p b 0.05). Seven differentially expressedmiRNAswere select-
ed, and their expression patterns were conﬁrmed in the validation phase; thus, miR-31-3p, -3676, -125a-5p, -
100-5p, -125b-5p, and -200a-5p and miR-342 were signiﬁcantly associated with clinical response. Expression
of this miRNA signature above the median level was a signiﬁcant predictor of non-response to standard treat-
ment (p b 0.001).
Conclusions. These seven validated miRNA signatures could be used as molecular biomarkers of chemo- and
radio-resistance in locally advanced cervical cancer patients.
© 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Cancerología, Laboratorio de
encia).
. This is an open access article under1. Introduction
Cervical cancer (CC) is an important health problem in developing
countries, where it ranks as the second leading cause of cancer-related
death [1]. Approximately 265,000 women died from CC in 2012; 87%
of them were in less developed countries [2]. Despite early detectionthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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vanced stages (LACC, stages IB2 to IVA according to FIGO) [3]. Standard
treatment for LACC patients consists of radiotherapy in combination
with cisplatin-based chemotherapy [4]. Unfortunately, nearly 50% of pa-
tients do not respond to standard treatment; these patients have a
higher recurrence rate and worse survival in the ﬁrst ﬁve years [5]. At
present, no speciﬁc molecular markers can predict the clinical response
of patients diagnosed with LACC.
MicroRNAs, or miRNAs, are small, non-coding RNAs that can post-
transcriptionally inhibit their target genes due to the complementarity
of bases to the 3′ non-translatable region (3′ UTR) of their target
mRNAs. miRNAs are key regulators of gene expression because of
their role in major biological processes, such as cell differentiation [6],
cell growth [7], apoptosis [8], hematopoiesis [9], viral infections [10],
and carcinogenesis [11–13].
Recently, several studies have investigated the role thatmiRNAs play
in tumor radio- and chemo-resistance. For instance, in non-small cell
lung cancer (NSCLC), nine miRNAs, including miR-29b-3p, miR-200a-
3p, and miR-126-3p were signiﬁcantly down-regulated, whereas miR-
208a was up-regulated in the serum of NSCLC patients after radiation
treatment (p b 0.05). Interestingly, miR-208a promotes cell prolifera-
tion and induces radio-resistance by targeting p21 with corresponding
activation of the AKT/mTOR pathway [14]. In breast cancer, ﬁvemiRNAs
have been associatedwith overall survival in patients receiving system-
ic therapy [15]. With respect to CC, Ke et al. found that over-expression
of miR-181a is linked to radio-resistance in locally advanced cervical
tumor samples; moreover, they demonstrated that the pro-apoptotic
protein kinase, PRKCD, is a validated target of miR-181a [16].
In the present study, we report a set of miRNAs that can be used as
molecular markers to predict clinical outcomes in LACC patients receiv-
ing radiation and chemotherapy treatment. We hypothesized that pri-
mary tumors have a set of miRNAs capable of predicting the potential
tumor response to conventional treatment; hence, the accurate identiﬁ-
cation of miRNAs that are involved in the innate resistance could be
employed as a prognosis signature associated with clinical response.
We identiﬁed a molecular signature consisting of seven validated
miRNAs (miR-31-3p, miR-3676, miR-342, miR-125a-5p, miR-125b-5p,
miR-100-5p and miR-200a-5p). Moreover, the bioinformatic analysis
revealed new potential signaling pathways that could be involved in
chemo-radiotherapy resistance phenotypes, such as the Wnt, Notch,
and ErbB signaling pathways.2. Materials and methods
2.1. Tumor samples
Upon diagnosis, 41 patients from the National Cancer Institute of
Mexico (INCan) were invited to participate in this study and enrolled
after they signed an informed consent form approved by the scientiﬁc
and ethics committees of the INCan. As soon as the biopsywas obtained,
the tumor samples were split into three pieces: one for pathologic con-
ﬁrmation of at least 80% of tumor cells, and the remaining two for RNA
and DNA isolation.
All patients in our study received the same standard treatment,
consisting of 5 weekly cycles of 40 mg/m2 of CDDP [cis-
diamminedichloroplatinum (II)] and 67 days of radiotherapy for a
total of 50–55 Gy in addition to 30 Gy of intracavitary brachytherapy.
Patients had follow-up appointments approximately every 3 or
4 months for the ﬁrst 2 years, every 6 months for the following
3 years, and annually thereafter. Patients who had a complete patholog-
ical response and “non-responders” (NRs) who had progressive disease
were randomly selected from this patient cohort. After a clinical follow-
up period of 45 months, we selected 41 patients who were categorized
into two groups (21 patientswho had a complete response (CRs) and 20
patients who had no response to clinical treatment or were NRs). In thisstudy, two patient cohortswere randomized formiRNA expression pro-
ﬁling, a discovery cohort (n = 10) and a validation cohort (n = 31).2.2. Clinical deﬁnitions
Clinical responses were evaluated using the RECIST 1.1 criteria and
computed axial tomography scans. The responses were classiﬁed as
complete response (CR), deﬁned as the disappearance of all signs of
cancer in response to treatment, and no response (NR), deﬁned as pa-
tients with partial, progressive, or stable disease [17].2.3. HPV genotyping in the tumor samples
The MagNAPure instrument was used to extract DNA from the
tumor samples according to the manufacturer's instructions. HPV
genotyping was performed using two methods: linear array HPV
genotyping and nested multiplex polymerase chain reaction (NM-PCR
MY/GP primers) followed by direct sequencing of the PCR fragment ac-
cording to previously reported processes [18].2.4. RNA extraction
Total RNA was extracted from the tumor samples using Trizol re-
agent (Invitrogen, CA Cat. #15596-026) and subsequently puriﬁed
with the miRNeasy Mini Kit (QIAGEN Cat. # 217004), according to the
manufacturer's instructions. RNA quantiﬁcation was performed using
an Epoch spectrophotometer (BioTek Instruments Inc.).2.5. miRNA expression proﬁles
miRNA expression proﬁles were measured using miScript miRNA
PCR Array (SABiosciences Cat. # 331222). Brieﬂy, 800 ng of RNA was
used to synthesize cDNA; qPCR reactions were then performed on a
LightCycler 480 (Roche, Manheim). The raw data were analyzed using
the Abs Quant/2nd Derivative Max method. Expression values were
normalized with respect to six endogenous miRNAs: SNORD61,
SNORD68, SNORD72, SNORD95, SNORD96A and RNU6B/RNU6-2; dif-
ferential expression was calculated using the Delta-Delta Ct method
[19].2.6. Statistical analysis
A t-test was used to identify signiﬁcant differences inmiRNA expres-
sion proﬁles between patients with a CR and those who were NRs.
miRNAswith a p b 0.05were considered to be signiﬁcant. Unsupervised
and supervised cluster hierarchical analyses were performed using
Bioconductor and Biobase, bioDist, gplots and gene ﬁlter packages im-
plemented in RStudio software (Ver. 0.98.501) [20].2.7. Validation of the miRNA proﬁle by RT-qPCR
Seven miRNAs were selected from the signiﬁcant group to be vali-
dated by a second quantiﬁcation method using TaqMan assays in the
validation cohort (n = 31). Brieﬂy, the reverse transcriptase reactions
contained 10 ngof total RNA, 3 μl of 5XRT primer, 1.5 μl of 10XRTbuffer,
0.25 mM of each dNTP, 50 U/μl of MultiScribe reverse transcriptase and
3.8 U/μl de RNase inhibitor. Reactions were performed in triplicate. Ex-
pression levels for both groups of patients (responders and non-re-
sponders) were determined using the Delta-Delta Ct method. We also
used the t-test with Welch's correlation to identify signiﬁcant differ-
ences between the complete response group and the group of patients
without pathological response to conventional therapy.
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A bioinformatic approach based on miRNA-target databases was
used to identify relevant mRNA targets and biological pathways. We
used the list of miRNAs that were signiﬁcant with p b 0.05 and had pre-
dicted mRNA-miRNA interactions. Finally, the resulting mRNA-miRNA
interactions were visualized in KEGG-mirPath v.3 [21].
2.9. Disease-free survival
Disease-free survival (DFS) rates, as related to the expression of the
validated seven-miRNA signature, were evaluated using the Kaplan-
Meier method. The signiﬁcance of the survival differences was deter-
mined by the log-rank test.
3. Results
3.1. Clinicopathologic characteristics
CC samples were collected from 41 patients with a clinical and path-
ological diagnosis of LACC (IB-IVA) at the INCan. All cervical samples
were analyzed histologically to conﬁrm a minimum of 80% of tumor
cells; conﬁrmed biopsies were then processed for nucleic acid isolation.
Table 1 lists themajor clinical characteristics of the patients. Themedian
age at diagnosis was 48 years (range 32 to 63 years). Themajority of pa-
tients were diagnosed as stages IIB (56.0%) and IIIB (26.8%); 85.3% had
squamous cell carcinoma, and 14.7% had adenocarcinoma. The main
HPV types were 16 (44.0%), 45 (24.4%) and 18 (19.5%). A relevant num-
ber of patients (17.1%) were infected with two or more HPV types. The
median duration of clinical follow-up was 45 months. Twenty-one pa-
tients (51.2%) were classiﬁed as NRs, whereas 20 (48.8%) had a CR.Table 1
Clinical and pathological characteristics of all patients involved in this study.
Characteristic Patients
N = 41
Age
Median 48
Range 29–68
Histological type
Squamous cell carcinoma 35 85.3%
Adenocarcinoma 6 14.7%
Tumor size
b4 cm 11 26.8%
≥4 cm 29 70.7%
Without data 1 2.5%
Clinical stage (FIGO)
IB2 2 4.87%
IIA 0 0.0%
IIB 26 63.41%
IIIA 0 0.0%
IIIB 11 26.82%
IVA 2 4.87%
VPH genotype (Frequency)
Type 16 12 29.26%
Type 18 7 17.07%
Type 45 10 24.29%
Others 4 9.75%
Patients with HPVcoinfection 7 17.07%
Not determined 1 2.43%
Treatment outcomea
Complete response 21 51.2%
No response 20 48.8%
Without date for desertion 0 0.0%
a All patients received radiotherapy and cisplatin as co-adjuvant (50 Gy external radi-
ation, 35 Gy intracavitary brachytherapy and 6 cycles of 40 mg/m2 CDDP).3.1.1. miRNA signature of LACC patients
The miRNA proﬁle was analyzed on an initial discovery cohort
(NR = 5; CR = 5), using miRbase v. 16, which contains 1066 mature
miRNAs. The median expression of each miRNA for both groups of pa-
tients was calculated and the differences between them were deter-
mined using the t-test. In total, 101 miRNAs showed signiﬁcant
differences between NR versus CR patients (p b 0.05; Supplementary
Table 1).
To identify amolecular proﬁle ofmiRNAs that could discriminate be-
tween the NR and CR patient groups, we employed a supervised classi-
ﬁcation approach based on expression values for each miRNA t-test
(p b 0.05) and a fold change ≥2 (Fig. 1). Interestingly, we found that
four miRNAs (hsa-miR144-3p, hsa-miR3176, hsa-miR31-3p and
miR3176) were over-expressed whereas 97 were down-regulated in
NR versus CR patients (Supplementary Table 1). SeveralmiRNA families
were represented, including the let-7 family (hsa-let-7d, hsa-let-7d*,
hsa-let-7g) located at 3p21.1 and hsa-let-7f-2* located at Xp11.22, the
miR-10 family (hsa-miR10a and hsa-miR-10a* located at 17q21.32,
hsa-miR-10b located at 2q31.1) and the miR-125 family (hsa-miR-
125a-5p located at 19q13.41, hsa-miR-125b located at 11q24.1 and
hsa-miR-125b-2* located at 21q21.1). These results suggest a coordi-
nate transcriptional regulation of the aforementioned chromosomal
regions.
3.2. Validation by qRT-PCR
To validate the above-mentioned miRNA signature in terms of clini-
cal response, we used a subset of 7 miRNAs (miR-31-3p, -3676, -125a-
5p, -100-5p, -125b-5p, and -200a-5p and miR-342), which were
assessed in an independent group of 31 samples from LACC patients
by TaqMan qRT-PCR assays (Fig. 2). The results were consistent with
the single miRNA qRT-PCR experiment and global expression data.
3.3. miRNA targets and signaling pathways associated with clinical
response
To understand the putative targets and signaling pathways associat-
ed with conventional treatment resistance in LACC patients, we used a
novel bioinformatic strategy that involved the identiﬁcation of
miRNA-mRNA regulatory pathways [22]. Therefore, we employed the
list of 101 signiﬁcantly de-regulated miRNAs between both groups of
patients. The algorithm selected those miRNA-mRNA pairs that had
three matches in different databases; one of the databases was
miRecords, which includes information from experimentally validated
data. Therefore, these identiﬁed mRNAs were considered bona ﬁde
miRNA target genes [23]. The selected mRNA targets were associated
with the signaling pathways in which they are involved. To obtain a
complete visualization of the signaling pathways based on mRNAs and
their respectivemiRNA regulators, themRNA targets and their associat-
ed miRNAs were visualized using KEGG-mirPath v.3. With this ap-
proach, we identiﬁed 18 miRNAs and 149 unique mRNA targets. The
miRNA-mRNA interactions were represented in 14 KEGG-pathways
that are associated with LACC patients who had no response to conven-
tional treatment (Supplementary Table 2).
Integrating themiRNA-mRNA target information, we found that the
most signiﬁcant biological pathways were previously involved in the
maintenance of the tumor phenotype, including pathways in cancer
(p = 3.34 e-19), the ErbB signaling pathway (p = 7.72 e-14), the Jak-
STAT signaling pathway (p = 2.793 e-02), Focal Adhesion (p =
5.825361 e-05), the Wnt signaling pathway (p = 2.06 e-02) and viral
carcinogenesis (p = 8.71 e-11) (Supplementary Table 2). Figs. 3 and 4
illustrate some of the most signiﬁcant pathways that maintain radio-
chemo-therapy-resistant phenotypes in CC (the ErbB, JAK-STAT, Wnt
and Focal Adhesion pathways); speciﬁc miRNA and mRNA interactions
are highlighted in red.
Fig. 1. Supervisedhierarchical clustering of 10 cervical cancer samples using expression data from101miRNAs.We employedheatmap.2 function and Euclidean correlation; a p b 0.05was
considered to identify signiﬁcantly differentially expressed miRNAs in patients with no response to conventional treatment. Columns display the clustering of tumor samples; rows
indicate the clustering of miRNA names. Patient clinical outcome is indicated by colored squares: red for no response and blue for complete response to conventional treatment. All
samples were properly assigned to the correct class based on the clinical outcome. The expression intensity of each miRNA in each sample varies from blue to red; for quantiﬁcation of
color codes, see color-bar on the left.
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DFS was assessed relative to the seven miRNA signatures in LACC.
Patients were dichotomized into two groups with low and high expres-
sion levels using themedian value for eachmiRNA as the cutoff. Expres-
sion of a miRNA signature above the median level was a signiﬁcant
predictor of NR status to standard treatment (p b 0.001). The NR
group had a mean DFS of 22 months; DFS has not yet been reached in
the complete response group (Fig. 5).4. Discussion
Several studies have suggested the use of miRNAs as biomarkers
in several types of diseases, particularly in cancer, in which the re-
sults have been encouraging [24–28]. To date, no miRNA subset
that can identify which LACC patients will not respond to conven-
tional therapy has yet been found. Here, we report a subset of 101
miRNAs that permit the accurate classiﬁcation of LACC patientsregarding clinical response, fromwhich sevenmiRNAwere validated
in an independent tumor cohort. These seven validated miRNA sig-
natures could be used as molecular biomarkers of chemo- and
radio-resistance.
Our results are similar to those published in a seminal work by Hu et
al. Those authors quantiﬁed 96 cancer-relatedmiRNAs in 59 FFPE cervi-
cal tumor tissues by a real-time PCR-basedmiRNA approach and report-
ed two miRNAs (miR-200a and miR-9) with the highest predictive
value associated with CC survival [29]. In our study, miR-200a was one
of the seven validated miRNAs that signiﬁcantly distinguished patients
who did not respond to standard treatment. In the qPCR experiments
used to obtain the global expression proﬁle of the miRNAs, miR-200a
was under-expressed 5.82 fold in non-response patients (p =
0.00028), while miR-200a was four times under-expressed in the
TaqMan probe validation experiments (p=0.0001). Along the same re-
search line, we identiﬁed the possible miR-200a molecular targets,
which include NRAS, NR4A1, MAPK8, PDGFA, TCF4, DKK2, PSEN1,
Fzd1, NOTCH2 and NOTCH4 and are associated with the MAPK, Wnt,
Notch and ErbB signaling pathways. Some of these pathways are
Fig. 2. Expression of seven differentially expressed miRNAs in 31 patients who constitute the validation cohort using TaqMan microRNA assays (NR = 15 and CR = 16). The relative
expression values for hsa-miR-125a, miR-125b, miR-100 and miR-200a, miR-31-3p, miR3676 and miR-342 could distinguish between patients with no response and complete
response to conventional treatment.
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related to radio- or chemo-resistance in CC.
In addition, we found that miR-100 could be used as a potential mo-
lecular marker to identify resistance to conventional treatment in LACC
patients,with signiﬁcant p values (p=0.034 in the global proﬁle resultsand p = 0.011 in the validation experiments). miR-100 was widely
studied by Li et al. in a group of 125 cervical tissue samples, which in-
cluded normal cervical epithelium, cervical intraepithelial neoplasias,
CC tissues and ﬁve cancer cell lines (HaCat, SiHa, CasKi, HeLa and
C33A). Li and colleagues reported that the expression of miR-100
Fig. 3.miRNA:mRNA interactions in the STAT and ErbBmolecular pathway associated with patients with no response to conventional treatment in LACC. Speciﬁc miRNAs are depicted in
red and down-regulation is indicated with an arrow.
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to high-grade lesions including cancer and HPV-positive cellular lines
[30]. Indeed, Polo-like kinase is a validated miR-100 target that is asso-
ciated with radio-sensitization or radio-resistance, depending on the
treatment schedule, in osteosarcoma and colorectal cancer [31].
Conﬁrming these ﬁndings, Yang X et al. reported that miR-100 ex-
pression is down-regulated in radio-resistant colorectal cancer samples.
Additionally, they demonstrated that miR-100 up-regulation sensitizes
CCL-244 cells to X-ray irradiation [32]. Interestingly, miR-100 is down-
regulated in cisplatin-resistant chondrosarcoma cells compared with
parental cell lines. Meanwhile, the ectopic over-expression of miR-100
results in the sensitization of cisplatin-resistant cells [33]. This study
and others conﬁrm the role of miR-100 in the regulation of chemo-
and radio-resistance phenotypes in human cancer [34,35].In our study, we identiﬁed several miRNAs that were previously as-
sociated with resistance to radiation and chemotherapy. For instance,
miR-125a, which promotes paclitaxel sensitivity in CC by altering
STAT3 expression,was down-regulated in non-responder LACCpatients
[36] (Fig. 2 and Supplementary Table 1). Up-regulation of miR-125b
confers resistance of ovarian cancer cells to cisplatin through suppres-
sion of Bak1 expression [37]; in contrast, in our data, miR-125b was
down-regulated in resistant tumors (Fig. 2, Supplementary Table 1).
miR-30c inhibits breast tumor chemotherapy resistance by regulating
TWF1 and IL-11 [38]; in the present study, miR-30c was also down-reg-
ulated in LACC patients with progressive disease (Supplementary Table
1). This ﬁnding suggests a common role of those miRNAs in the regula-
tion of mechanisms leading to radio- and chemotherapy resistance in
human tumors.
Fig. 4.miRNA:mRNA interactions in the Focal Adhesion andWnt molecular pathways associated with patients with no response to conventional treatment in LACC. Speciﬁc miRNAs are
depicted in red and down-regulation is indicated with an arrow.
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7 family (hsa-let-7d, hsa-let-7d*, hsa-let-7f-2, and hsa-let-7g). Previous
studies have shown that the expression of let-7g is modulated by ioniz-
ing radiation in human endothelial cells [39]. In our ﬁndings, let-7g had
a 3-fold overexpression in patients with complete response. Similarly,
Arora and colleagues reported that let-7g enhances sensitivity to ioniz-
ing radiation by the suppression of NFκB1 in lung cancer [40]. An exten-
sive review of published studies had reported deregulation of eight
members of the let-7 family (let-7a, let-7b, let-7c, let-7d, let-7e, let-7f,
let-7g and let-7i) in response to ionizing radiation on distinct cancer-
derived cell lines [41].More signiﬁcantly, the miRNAs reported here, including miR-3176,
miR-3676, miR-502, miR-128, miR-145, miR-651, miR-299, miR-548,
and miR-345, are for the ﬁrst time associated with the development of
resistance in LACC patients.
The list of miRNAs identiﬁed in this study has been associated with
the development of resistance to radio- and chemotherapy through
the regulation of key genes that participate in theMAPK andWnt signal-
ing pathways, apoptosis, and the cell cycle. However, we identiﬁed
three signaling pathways that were not previously associated with re-
sistance: Jak-STAT, Notch and ErbB. Thus, the association of the afore-
mentioned molecular pathways with chemo- and radio-resistant
Fig. 5. Kaplan-Meier DFS analysis based on 7 validated miRNA signatures. The behavior of
the seven-miRNA proﬁle for patients with no response to conventional treatment is
shown by a dotted line, and that for patients with a complete response is shown by a
continuous line; both groups are clearly separated within the ﬁrst months (n = 41
patients). Clinical response was assessed according to RECIST 1.1. The log rank Mantel-
cox test identiﬁed signiﬁcant differences (p = 0.001) between the groups of patients
(95% CI, 0.014–0.052).
564 A. Pedroza-Torres et al. / Gynecologic Oncology 142 (2016) 557–565phenotypes provides insights into new pharmacological targets that
could be used in the near future to develop better therapeutic strategies
for CC patients.
Our results propose a subset ofmiRNAs related to radio- and chemo-
resistance in LACC patients. Deeper and more exhaustive validation
analyseswith functional assays to evaluate the speciﬁc roles of the iden-
tiﬁed miRNAs in the regulation of the tumor cells' radio- and chemo-
therapy responses are needed.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.ygyno.2016.07.093.
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